New trial
Spotlight
Phase 1/2 trial ARV-806 KRAS (G12D) inhibitor in advanced cancer.
- Trial ID
- NCT07023731 on ClinicalTrials.gov
- Cancer type
- Other Solid Tumors
- Stage of research
- First-in-human
- Published in
- New in Oncology - July 3, 2025
This open-label Phase 1/2 study evaluates ARV-806 administered via IV infusion in adults with advanced KRAS G12D-mutated tumors, including metastatic pancreatic ductal adenocarcinoma. Sponsored by Arvinas Inc. and conducted in Fairfax, the trial seeks to determine optimal dosing and assess early anti-tumor activity in a first-in-human setting.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings